Should You Buy Quest Diagnostics Ahead of Earnings?

Quest Diagnostics (DGX) is positioned for a potential earnings beat, with recent analyst estimate revisions pushing the Most Accurate Estimate to $2.59 per share, slightly above the Zacks Consensus Estimate of $2.57. This results in a positive Zacks Earnings ESP of +0.67%. Coupled with DGX's Zacks Rank #3 (Hold), this combination historically indicates a high probability of an earnings surprise and positive post-earnings performance.

Analysis

Recent upward revisions in analyst estimates for Quest Diagnostics (DGX) indicate a heightened probability of a positive earnings surprise in its upcoming report. The Most Accurate Estimate for the current quarter stands at $2.59 per share, exceeding the broader Zacks Consensus Estimate of $2.57. This differential results in a positive Earnings ESP (Expected Surprise Prediction) of +0.67%. The significance of this metric is amplified by the stock's Zacks Rank #3 (Hold); historical back-testing cited in the report shows that this combination has preceded a positive earnings surprise nearly 70% of the time. This specific quantitative signal suggests that analysts with the most current information have identified favorable underlying trends, positioning DGX for a potential outperformance relative to market expectations.

Key Decisions for Investors

• Given the positive Earnings ESP of +0.67% and its historically high correlation with earnings outperformance, investors might consider DGX as a tactical long position heading into the earnings announcement.
• This bullish short-term signal should be balanced against the stock's neutral Zacks Rank #3 (Hold), suggesting any position should be sized appropriately, as the underlying fundamental outlook is not rated as a 'Strong Buy'.
• Investors should prioritize analysis of the actual earnings quality and management's forward guidance post-announcement, as these factors will be more critical for the sustained price reaction than a simple headline EPS beat.